PTC (NASDAQ:PTC) Stock Sale Revealed by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros Jr. sold $1,001–$15,000 of PTC stock on September 17 from a Bank of America trust account. He also reported several other stock purchases and sales in late September and early October.
• PTC shares were trading near $193.96, with a market capitalization of $21.05 billion. The company narrowly exceeded quarterly EPS expectations, but revenue fell 6.8% year over year to $600.05 million.
• Analysts have largely adopted a cautious stance, with multiple firms downgrading PTC to neutral, equal weight, or hold. The stock carries a consensus “Hold” rating and an average price target of $200.06.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of PTC Inc. (NASDAQ:PTC). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in PTC stock on September 17th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.

PTC Trading Down 0.2%

Shares of PTC opened at $193.96 on Wednesday. The firm's 50-day moving average price is $151.02 and its 200-day moving average price is $139.16. The firm has a market capitalization of $21.05 billion, a price-to-earnings ratio of 24.42, a PEG ratio of 2.55 and a beta of 0.99. The company has a current ratio of 1.03, a quick ratio of 1.03 and a debt-to-equity ratio of 0.40. PTC Inc. has a 1-year low of $108.50 and a 1-year high of $206.82.

PTC (NASDAQ:PTC - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The technology company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.57 by $0.01. PTC had a net margin of 41.67% and a return on equity of 25.31%. The company had revenue of $600.05 million during the quarter, compared to the consensus estimate of $611.62 million. During the same period in the prior year, the firm earned $1.64 earnings per share. PTC's revenue was down 6.8% on a year-over-year basis. PTC has set its FY 2026 guidance at 7.870-8.420 EPS and its Q4 2026 guidance at 1.630-2.210 EPS. Sell-side analysts anticipate that PTC Inc. will post 6.51 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. KeyCorp downgraded PTC from an "overweight" rating to a "sector weight" rating in a report on Monday, October 5th. BMO Capital Markets cut shares of PTC from an "outperform" rating to a "market perform" rating and boosted their target price for the company from $164.00 to $205.00 in a report on Tuesday, October 6th. Barclays cut shares of PTC from an "overweight" rating to an "equal weight" rating and lifted their price target for the company from $155.00 to $205.00 in a research report on Monday, October 5th. Loop Capital cut shares of PTC from a "buy" rating to a "hold" rating and upped their price objective for the stock from $200.00 to $205.00 in a report on Monday, October 5th. Finally, BNP Paribas Exane initiated coverage on shares of PTC in a research note on Thursday, June 18th. They set a "neutral" rating and a $130.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $200.06.

Institutional Investors Weigh In On PTC

A number of institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC boosted its holdings in shares of PTC by 89.3% during the 1st quarter. Renaissance Technologies LLC now owns 389,100 shares of the technology company's stock valued at $55,443,000 after purchasing an additional 183,600 shares during the last quarter. SCS Capital Management LLC bought a new stake in shares of PTC in the second quarter worth about $37,912,000. Amundi increased its holdings in shares of PTC by 151.9% in the first quarter. Amundi now owns 1,725,555 shares of the technology company's stock worth $245,885,000 after purchasing an additional 1,040,656 shares during the last quarter. Hsbc Holdings PLC lifted its position in shares of PTC by 65.0% in the second quarter. Hsbc Holdings PLC now owns 587,782 shares of the technology company's stock worth $66,753,000 after buying an additional 231,563 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of PTC by 104.5% in the second quarter. Assenagon Asset Management S.A. now owns 224,989 shares of the technology company's stock worth $25,561,000 after buying an additional 114,961 shares in the last quarter. Hedge funds and other institutional investors own 95.14% of the company's stock.

Insider Buying and Selling

In other PTC news, Director Corinna Lathan sold 1,750 shares of the firm's stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $195.75, for a total transaction of $342,562.50. Following the completion of the transaction, the director owned 6,679 shares in the company, valued at $1,307,414.25. This trade represents a 20.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.29% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About PTC

PTC Inc NASDAQ: PTC develops software designed to help manufacturers and other industrial companies create, manage, operate and service physical products. Its portfolio supports product lifecycle management, computer-aided design, application lifecycle management, service lifecycle management, industrial Internet of Things applications and augmented reality.

PTC's primary products include Creo for 3D computer-aided design and engineering, Windchill for product lifecycle management, Codebeamer for application lifecycle management, and Servigistics for service parts and service operations management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.